AURA 2021 is the fourth in a series of national reports on the critical issues of antimicrobial resistance (AMR), and the use of antimicrobials (AU), in Australia.

The focus of Chapter 3 is antimicrobial use and the appropriateness of use in Australia; this resource provides figures and tables for use in presentations and other documents, to allow ease of access to data at the local level, and for all jurisdictions. 

The Consumer Summary provides an overview of the key findings and messages of AURA 2021 for consumers.

This resource provides a summary of some of the key data from AURA 2021 that may be of specific interest to public health professionals.

This resource provides a summary of AURA 2021 data that may be of specific interest to members of infection prevention and control teams.

This resource provides a summary of AURA 2021 data that may be of specific interest to medical practitioners.

This resource provides a summary of AURA 2021 data that may be of specific interest to hospital and community pharmacists.

This report provides supplementary data relevant to Chapter 4 of AURA 2021 - Antimicrobial resistance.

This report includes analyses of antimicrobial resistance and antimicrobial use data predominantly collected in 2018 and 2019, and 2020 data from the National Alert System for Critical Antimicrobial Resistances (CARAlert) the Pharmaceutical Benefits Scheme (PBS) in the context of the COVID-19 pandemic.

This issue includes items on COVID-19, medication safety, community pharmacy, paediatric mediation errors, mental health, healthcare associated infections and more.

Also covered are the latest issues of the Australian Journal of Primary Health Review, Patient Experience Journal and Pediatric Quality & Safety along with the latest online papers from BMJ Quality & Safety and International Journal for Quality in Health Care and the latest from the UK’s NICE and the USA’s AHRQ.